Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R. Gaudinski(National Institute of Allergy and Infectious Diseases)PLoS MedicineJanuary 24, 201810.1371/journal.pmed.1002493Cited by 253SaveCiteExport RISWatch citationsRelated PapersClonal hematopoiesis is not significantly associated with COVID-19 disease severity|Blood|2022|25Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials|npj Vaccines|2024|19